Articles
Page 3 of 28
-
Citation: Alzheimer's Research & Therapy 2022 14:131
-
Immune-mediated diseases are associated with a higher incidence of dementia: a prospective cohort study of 375,894 individuals
Immune system dysregulation plays a vital role in the pathogenesis of neurodegenerative diseases, even considered to be as important as classical pathological protein aggregation assumption. However, the assoc...
Citation: Alzheimer's Research & Therapy 2022 14:130 -
Predicting conversion of brain β-amyloid positivity in amyloid-negative individuals
Cortical deposition of β-amyloid (Aβ) plaque is one of the main hallmarks of Alzheimer’s disease (AD). While Aβ positivity has been the main concern so far, predicting whether Aβ (−) individuals will convert t...
Citation: Alzheimer's Research & Therapy 2022 14:129 -
Association of the inflammation-related proteome with dementia development at older age: results from a large, prospective, population-based cohort study
Chronic inflammation is a central feature of several forms of dementia. However, few details on the associations of blood-based inflammation-related proteins with dementia incidence have been explored yet.
Citation: Alzheimer's Research & Therapy 2022 14:128 -
Diagnostic performance of automated plasma amyloid-β assays combined with pre-analytical immunoprecipitation
Measurements of the amyloid-β (Aβ) 42/40 ratio in blood plasma may support the early diagnosis of Alzheimer’s disease and aid in the selection of suitable participants in clinical trials. Here, we compared the...
Citation: Alzheimer's Research & Therapy 2022 14:127 -
Subjective cognitive decline and anxious/depressive symptoms during the COVID-19 pandemic: what is the role of stress perception, stress resilience, and β-amyloid?
The COVID-19 pandemic may worsen the mental health of people reporting subjective cognitive decline (SCD) and therefore their clinical prognosis. We aimed to investigate the association between the intensity o...
Citation: Alzheimer's Research & Therapy 2022 14:126 -
Effects of a mindfulness-based versus a health self-management intervention on objective cognitive performance in older adults with subjective cognitive decline (SCD): a secondary analysis of the SCD-Well randomized controlled trial
Older individuals with subjective cognitive decline (SCD) perceive that their cognition has declined but do not show objective impairment on neuropsychological tests. Individuals with SCD are at elevated risk ...
Citation: Alzheimer's Research & Therapy 2022 14:125 -
Longitudinal change in ATN biomarkers in cognitively normal individuals
Biomarkers for amyloid, tau, and neurodegeneration (ATN) have predictive value for clinical progression, but it is not clear how individuals move through these stages. We examined changes in ATN profiles over ...
Citation: Alzheimer's Research & Therapy 2022 14:124 -
Neural correlates of episodic memory in adults with Down syndrome and Alzheimer’s disease
Adults with Down syndrome are at an ultra-high risk of developing early-onset Alzheimer’s disease. Episodic memory deficits are one of the earliest signs of the disease, but their association with regional bra...
Citation: Alzheimer's Research & Therapy 2022 14:123 -
Static and dynamic functional connectivity variability of the anterior-posterior hippocampus with subjective cognitive decline
Subjective cognitive decline (SCD) is a putative Alzheimer’s disease (AD) precursor without objective neuropsychological deficits. The hippocampus plays an important role in cognitive function and emotional re...
Citation: Alzheimer's Research & Therapy 2022 14:122 -
Dynamic network model reveals distinct tau spreading patterns in early- and late-onset Alzheimer disease
The clinical features of Alzheimer’s disease (AD) vary substantially depending on whether the onset of cognitive deficits is early or late. The amount and distribution patterns of tau pathology are thought to ...
Citation: Alzheimer's Research & Therapy 2022 14:121 -
Hypnosis for pain and anxiety management in cognitively impaired older adults undergoing scheduled lumbar punctures: a randomized controlled pilot study
Core cerebrospinal fluid (CSF) amyloid and tau biomarker assessment has been recommended to refine the diagnostic accuracy of Alzheimer’s disease. Lumbar punctures (LP) are invasive procedures that might induc...
Citation: Alzheimer's Research & Therapy 2022 14:120 -
Rationale and design of the “NEurodegeneration: Traumatic brain injury as Origin of the Neuropathology (NEwTON)” study: a prospective cohort study of individuals at risk for chronic traumatic encephalopathy
Repetitive head injury in contact sports is associated with cognitive, neurobehavioral, and motor impairments and linked to a unique neurodegenerative disorder: chronic traumatic encephalopathy (CTE). As the c...
Citation: Alzheimer's Research & Therapy 2022 14:119 -
Differential impairment of cerebrospinal fluid synaptic biomarkers in the genetic forms of frontotemporal dementia
Approximately a third of frontotemporal dementia (FTD) is genetic with mutations in three genes accounting for most of the inheritance: C9orf72, GRN, and MAPT. Impaired synaptic health is a common mechanism in al...
Citation: Alzheimer's Research & Therapy 2022 14:118 -
Increased plasma and brain immunoglobulin A in Alzheimer’s disease is lost in apolipoprotein E ε4 carriers
Alzheimer’s disease (AD) is foremost characterized by β-amyloid (Aβ)-extracellular plaques, tau-intraneuronal fibrillary tangles (NFT), and neuroinflammation, but over the last years it has become evident that...
Citation: Alzheimer's Research & Therapy 2022 14:117 -
Choroid and choriocapillaris changes in early-stage Parkinson’s disease: a swept-source optical coherence tomography angiography-based cross-sectional study
Parkinson’s disease (PD) is one of the most common neurodegenerative diseases in the aging population. Previous literature has reported thinning of the retinal nerve fiber layer, ganglion cell layer, inner ple...
Citation: Alzheimer's Research & Therapy 2022 14:116 -
Plasma apolipoprotein E levels in longitudinally followed patients with mild cognitive impairment and Alzheimer’s disease
Low levels of plasma apolipoprotein E (apoE) and presence of the APOE ε4 allele are associated with an increased risk of Alzheimer’s disease (AD). Although the increased risk of AD in APOE ε4-carriers is well-est...
Citation: Alzheimer's Research & Therapy 2022 14:115 -
Tau levels are higher in objective subtle cognitive decline but not subjective memory complaint
The 2018 NIA-AA Alzheimer’s Disease (AD) Research Framework states that subtle cognitive decline in cognitively unimpaired individuals can be measured by subjective reports or evidence of objective decline on ...
Citation: Alzheimer's Research & Therapy 2022 14:114 -
Italian adaptation of the Uniform Data Set Neuropsychological Test Battery (I-UDSNB 1.0): development and normative data
Neuropsychological testing plays a cardinal role in the diagnosis and monitoring of Alzheimer’s disease. A major concern is represented by the heterogeneity of the neuropsychological batteries currently adopte...
Citation: Alzheimer's Research & Therapy 2022 14:113 -
Perspectives and challenges in patient stratification in Alzheimer’s disease
Patient stratification is the division of a patient population into distinct subgroups based on the presence or absence of particular disease characteristics. As patient stratification can be used to account f...
Citation: Alzheimer's Research & Therapy 2022 14:112 -
An explainable self-attention deep neural network for detecting mild cognitive impairment using multi-input digital drawing tasks
Mild cognitive impairment (MCI) is an early stage of cognitive decline which could develop into dementia. An early detection of MCI is a crucial step for timely prevention and intervention. Recent studies have...
Citation: Alzheimer's Research & Therapy 2022 14:111 -
Development of multivariable prediction models for institutionalization and mortality in the full spectrum of Alzheimer’s disease
Patients and caregivers express a desire for accurate prognostic information about time to institutionalization and mortality. Previous studies predicting institutionalization and mortality focused on the deme...
Citation: Alzheimer's Research & Therapy 2022 14:110 -
Investigating the power of eyes open resting state EEG for assisting in dementia diagnosis
The differentiation of Lewy body dementia from other common dementia types clinically is difficult, with a considerable number of cases only being found post-mortem. Consequently, there is a clear need for ine...
Citation: Alzheimer's Research & Therapy 2022 14:109 -
Discovery and validation of dominantly inherited Alzheimer’s disease mutations in populations from Latin America
In fewer than 1% of patients, AD is caused by autosomal dominant mutations in either the presenilin 1 (PSEN1), presenilin 2 (PSEN2), or amyloid precursor protein (APP) genes. The full extent of familial AD and fr...
Citation: Alzheimer's Research & Therapy 2022 14:108 -
Early diagnosis of Alzheimer’s disease using machine learning: a multi-diagnostic, generalizable approach
Early and accurate diagnosis of Alzheimer’s disease (AD) is essential for disease management and therapeutic choices that can delay disease progression. Machine learning (ML) approaches have been extensively u...
Citation: Alzheimer's Research & Therapy 2022 14:107 -
Inflammatory plasma biomarkers in subjects with preclinical Alzheimer’s disease
This study investigated plasma biomarkers for neuroinflammation associated with Alzheimer’s disease (AD) in subjects with preclinical AD compared to healthy elderly. How these biomarkers behave in patients wit...
Citation: Alzheimer's Research & Therapy 2022 14:106 -
Evaluation of tau deposition using 18F-PI-2620 PET in MCI and early AD subjects—a MissionAD tau sub-study
The ability of 18F-PI-2620 PET to measure the spatial distribution of tau pathology in Alzheimer’s disease (AD) has been demonstrated in previous studies. The objective of this work was to evaluate tau deposition...
Citation: Alzheimer's Research & Therapy 2022 14:105 -
Deletion of Abi3/Gngt2 influences age-progressive amyloid β and tau pathologies in distinctive ways
The S209F variant of Abelson Interactor Protein 3 (ABI3) increases risk for Alzheimer’s disease (AD), but little is known about its function in relation to AD pathogenesis.
Citation: Alzheimer's Research & Therapy 2022 14:104 -
Krüppel-like factor 5 accelerates the pathogenesis of Alzheimer’s disease via BACE1-mediated APP processing
The deposition of β-amyloid (Aβ) in the brain plays a major role in the pathogenesis of Alzheimer’s disease (AD). Aβ is generated via amyloid precursor protein (APP) cleavage through the amyloidogenic pathway....
Citation: Alzheimer's Research & Therapy 2022 14:103 -
Issues and recommendations for the residual approach to quantifying cognitive resilience and reserve
Cognitive reserve and resilience are terms used to explain interindividual variability in maintenance of cognitive health in response to adverse factors, such as brain pathology in the context of aging or neur...
Citation: Alzheimer's Research & Therapy 2022 14:102 -
A multiscale brain network model links Alzheimer’s disease-mediated neuronal hyperactivity to large-scale oscillatory slowing
Neuronal hyperexcitability and inhibitory interneuron dysfunction are frequently observed in preclinical animal models of Alzheimer’s disease (AD). This study investigates whether these microscale abnormalitie...
Citation: Alzheimer's Research & Therapy 2022 14:101 -
YKL-40 changes are not detected in post-mortem brain of patients with Alzheimer’s disease and frontotemporal lobar degeneration
YKL-40 (Chitinase 3-like I) is increased in CSF of Alzheimer’s disease (AD) and frontotemporal lobar degeneration (FTLD) patients and is therefore considered a potential neuroinflammatory biomarker. Whether ch...
Citation: Alzheimer's Research & Therapy 2022 14:100 -
Decreased visual acuity is related to thinner cortex in cognitively normal adults: cross-sectional, single-center cohort study
Decreased visual acuity (VA) is reported to be a risk factor for dementia. However, the association between VA and cortical thickness has not been established. We investigated the association between VA and co...
Citation: Alzheimer's Research & Therapy 2022 14:99 -
Grey matter changes on brain MRI in subjective cognitive decline: a systematic review
People with subjective cognitive decline (SCD) report cognitive deterioration. However, their performance in neuropsychological evaluation falls within the normal range. The present study aims to analyse wheth...
Citation: Alzheimer's Research & Therapy 2022 14:98 -
The effects of exercise programs on cognition, activities of daily living, and neuropsychiatric symptoms in community-dwelling people with dementia—a systematic review
The prevalence of dementia is expected to increase dramatically. Due to a lack of pharmacological treatment options for people with dementia, non-pharmacological treatments such as exercise programs have been ...
Citation: Alzheimer's Research & Therapy 2022 14:97 -
Prodromal characteristics of dementia with Lewy bodies: baseline results of the MEMENTO memory clinics nationwide cohort
Isolated subjective cognitive impairment (SCI) and mild cognitive impairment (MCI) are the prodromal phases of dementia with Lewy bodies (DLB). MEMENTO is a nationwide study of patients with SCI and MCI with c...
Citation: Alzheimer's Research & Therapy 2022 14:96 -
P-tau subgroups in AD relate to distinct amyloid production and synaptic integrity profiles
We previously identified four Alzheimer’s disease (AD) subgroups with increasingly higher cerebrospinal fluid (CSF) levels of tau phosphorylated at threonine 181 (p-tau). These subgroups included individuals a...
Citation: Alzheimer's Research & Therapy 2022 14:95 -
Multidomain trials to prevent dementia: addressing methodological challenges
Multidomain trials to prevent dementia by simultaneously targeting multiple risk factors with non-pharmacological lifestyle interventions show promise. Designing trials to evaluate the efficacy of individual i...
Citation: Alzheimer's Research & Therapy 2022 14:94 -
The impact of subthreshold levels of amyloid deposition on conversion to dementia in patients with amyloid-negative amnestic mild cognitive impairment
About 40–50% of patients with amnestic mild cognitive impairment (MCI) are found to have no significant Alzheimer’s pathology based on amyloid PET positivity. Notably, conversion to dementia in this population...
Citation: Alzheimer's Research & Therapy 2022 14:93 -
Phosphodiesterase 5 inhibitor mirodenafil ameliorates Alzheimer-like pathology and symptoms by multimodal actions
Alzheimer’s disease (AD) pathology is associated with complex interactions among multiple factors, involving an intertwined network of various signaling pathways. The polypharmacological approach is an emergin...
Citation: Alzheimer's Research & Therapy 2022 14:92 -
Associations between proton pump inhibitors and Alzheimer’s disease: a nested case–control study using a Korean nationwide health screening cohort
Safety concerns against the use of proton pump inhibitors (PPIs) based on the risk of dementia, especially Alzheimer’s disease (AD), remain controversial. Here, we investigated the likelihood of AD depending o...
Citation: Alzheimer's Research & Therapy 2022 14:91 -
Genetic prion diseases presenting as frontotemporal dementia: clinical features and diagnostic challenge
To elucidate the clinical and ancillary features of genetic prion diseases (gPrDs) presenting with frontotemporal dementia (FTD) to aid early identification.
Citation: Alzheimer's Research & Therapy 2022 14:90 -
White matter hyperintensities are a prominent feature of autosomal dominant Alzheimer’s disease that emerge prior to dementia
To promote the development of effective therapies, there is an important need to characterize the full spectrum of neuropathological changes associated with Alzheimer’s disease. In line with this need, this st...
Citation: Alzheimer's Research & Therapy 2022 14:89 -
Imipramine and olanzapine block apoE4-catalyzed polymerization of Aβ and show evidence of improving Alzheimer’s disease cognition
The apolipoprotein E (APOE) ε4 allele confers the strongest risk for late-onset Alzheimer’s disease (AD) besides age itself, but the mechanisms underlying this risk are debated. One hypothesis supported by eviden...
Citation: Alzheimer's Research & Therapy 2022 14:88 -
Effect of the ABCA1 agonist CS-6253 on amyloid-β and lipoprotein metabolism in cynomolgus monkeys
Inducing brain ATP-binding cassette 1 (ABCA1) activity in Alzheimer’s disease (AD) mouse models is associated with improvement in AD pathology. The purpose of this study was to investigate the effects of the A...
Citation: Alzheimer's Research & Therapy 2022 14:87 -
Fully automated and highly specific plasma β-amyloid immunoassays predict β-amyloid status defined by amyloid positron emission tomography with high accuracy
Clinicians, researchers, and patients alike would greatly benefit from more accessible and inexpensive biomarkers for neural β-amyloid (Aβ). We aimed to assess the performance of fully automated plasma Aβ immu...
Citation: Alzheimer's Research & Therapy 2022 14:86 -
Anticipated reactions to learning Alzheimer’s disease biomarker results
We developed the Alzheimer’s Biomarker Survey to assess willingness to enroll in biomarker studies that disclose results and anticipated reactions to an elevated biomarker result.
Citation: Alzheimer's Research & Therapy 2022 14:85 -
Near-infrared light reduces β-amyloid-stimulated microglial toxicity and enhances survival of neurons: mechanisms of light therapy for Alzheimer’s disease
Low-intensity light can decelerate neurodegenerative disease progression and reduce amyloid β (Aβ) levels in the cortex, though the cellular and molecular mechanisms by which photobiomodulation (PBM) protects ...
Citation: Alzheimer's Research & Therapy 2022 14:84 -
Hormone therapy and the decreased risk of dementia in women with depression: a population-based cohort study
The literature has shown depression to be associated with an increased risk of dementia. In addition, hormone therapy can be a responsive treatment option for a certain type of depression. In this study, we ex...
Citation: Alzheimer's Research & Therapy 2022 14:83 -
Correction: Diagnostic and prognostic performance to detect Alzheimer’s disease and clinical progression of a novel assay for plasma p-tau217
Citation: Alzheimer's Research & Therapy 2022 14:82
Follow
- ISSN: 1758-9193 (electronic)